Full Transcript Welcome to The Trip Lab 0:01 [music] Welcome to the trip lab kitchen table 0:05 conversations about integrative medicine and psychedelics. [music] 0:08 I'm your host and attending physician Dr. Mariela Wood. 0:14 Evidence-based medicine is essential. It's the reason medicine has advanced as 0:18 far as it has. Why we survive diseases that would have been fatal just a 0:22 century ago. And why modern healthcare has been able to reduce suffering at a 0:26 scale that was once unimaginable. And some of the most powerful medical 0:30 advances weren't even high-tech. So things like handwashing or clean 0:35 drinking water and sanitation that dramatically altered human survival. And 0:40 alongside those foundational public health innovations, evidence-based 0:43 research gave us life-saving surgeries, antibiotics, cardiovascular 0:47 interventions, and medications that have unquestionably changed outcomes. So let 0:52 me be very clear at the start of this episode. This is not a rejection of 0:56 evidence-based medicine. This is a scrutiny of what evidence-based medicine 1:00 actually is right now and how we can reclaim evidence in a way that matches 1:04 the pace of our technological advancements. What I've witnessed over 1:08 the past decade, and something that began long before I even graduated 1:12 medical school, is a quiet but important shift. Evidence-based medicine has 1:18 increasingly become reductionist medicine. I first began to think about 1:22 this and seriously question this during my surgical training. I actually started 1:25 out in general surgery residency before pivoting to my current career in 1:29 integrative medicine. So on ICU or critical care rotations, we would 1:33 scrutinize the literature in painstaking detail. Decisions like normal saline 1:38 versus lactated ringers were debated intensely with statistical analyses 1:42 parsed down to fractional differences. One option would be chosen because it 1:46 was slightly better in the data. And to be clear again, that process is not 1:50 wrong. That rigor is part of what keeps patients safe. But watching all of this 1:54 play out made me step back and ask a deeper question. What do we actually
Evidence-Based Medicine vs Reductionism 1:58 mean when we say something is evidence-based? And how much clinical 2:02 meaning are we assigning to very small statistical differences? So that 2:06 question stayed with me and then co happened. So suddenly we were facing a 2:11 novel disease with no established evidence base. 2:15 There were no guidelines, no long-term outcome data, no randomized trials to 2:20 learn on. So clinicians and patients alike were reaching for anything that 2:24 felt potentially helpful, often highdosese vitamins, supplements, and 2:28 lifestylebased interventions. We even played around with highdose 2:32 vitamins given through IVs in the co ICUs, something that I never thought I 2:36 would be doing in general surgery residency. So that got me curious. I 2:40 started reading and what I found surprised me. Many integrative therapies 2:44 had comparable levels of evidence to interventions we routinely use in 2:48 conventional medicine and sometimes even more. Take blood pressure as an example. 2:53 On average, many anti-hypertensive medications lower systolic blood 2:57 pressure by about 7 to 15 points. And that is meaningful, but so does a 3:02 Mediterranean lifestyle. So do interventions like regular physical 3:06 exercise, stress reduction, and even certain supplements like co-enzyme Q10. 3:11 And these lifestyle or integrative options actually get to the root cause 3:15 and change the system that's been damaged where blood pressure drugs just 3:19 solely lower the blood pressure. Now, just lowering the blood pressure does 3:23 have its benefits in preventing kidney disease and earlier heart attacks. But 3:27 if we're not truly treating the root cause of why high blood pressure 3:31 manifested, something else or worse will get you because the system was not 3:35 fixed. Just a blood pressure number was. So, why don't we talk about these 3:39 lifestyle or integrative therapies in modern medicine spaces? Why don't we 3:43 learn about them in medical school? Why did I just have one single hour of 3:48 nutrition training throughout the 20,000 hours it takes to go through medical 3:52 school and residency? And it's not because it's not effective. It's money. 3:57 There was no financial incentive to rigorously study lifestyle interventions 4:00 at scale. Drugs generate profit. Lifestyle does not. And so the evidence 4:05 base itself becomes skewed, not because something doesn't work, but because it 4:09 isn't lucrative to study. I dive deeper into the history behind this in episode 4:13 15, which is my deep dive series intro. The episode's called How Big Pharma led 4:17 Used to Call Eastern Medicine Alternative, if you want a more 4:20 historical lens. But in this episode, we're going to focus on now. We're going 4:25 to talk about what evidence-based medicine was meant to be, how it slowly 4:29 became overly reductionist, and why that matters, especially in chronic disease. 4:35 We'll examine how guidelines are created, how clinical significance gets 4:39 lost in statistical language, and why patients so often feel unwell even when 4:43 they're told their labs are normal. And then we're going to rebuild. We're going 4:47 to talk about what a more integrated, systemaware, and clinically wise version 4:51 of evidence-based medicine actually looks like. One that patients are asking 4:55 for, that many physicians feel but don't always have language for, and that I 5:00 believe represents the future of medicine. Before we go any further, I 5:03 want to briefly acknowledge the name of this podcast, The Trip Lab. While the 5:08 name obviously nods to psychedelic medicine, which is a major focus of this 5:12 show, a trip also means something broader. It's an exploration, a 5:17 willingness to step outside of familiar frameworks and examine what happens when 5:21 we look more closely, more curiously, and more honestly. That is what I intend 5:27 to do with this podcast and my career. To explore the frontiers of medicine and 5:32 elsewhere, to question what we assume we already know and to better understand 5:36 how systems connect rather than treating them in isolation. 5:41 Life is a trip and meaning is made through exploration, reflection, and 5:45 intentional change. But back to this episode, one core idea that should lead 5:50 us to examine evidence with more scrutiny is the difference between 5:53 statistical significance and clinical significance.
Statistical vs Clinical Significance 5:57 We use these terms all the time in medicine, but I don't think we pause 6:00 often enough to ask what they actually mean in practice. Statistical 6:04 significance tells us whether an observed effect is unlikely to be due to 6:08 chance. It answers a very narrow question. Is [clears throat] this result 6:12 mathematically real? Clinical significance asks something 6:16 very different. Does this meaningfully change a patient's life? Those two 6:20 things are not the same. And yet in modern medicine, we often treat them as 6:24 if they are interchangeable. A result can be statistically significant but 6:28 still be clinically trivial. With a large enough sample size, even very 6:32 small differences can reach statistical significance. And in isolation, those 6:37 numbers can look impressive. But when you zoom out and ask whether that 6:41 difference actually changes how a patient feels, functions, or survives, 6:45 the answer is often much less clear. This is where I first started to feel 6:49 uneasy during my training. In critical care and inpatient medicine, we would 6:53 agonize over studies comparing interventions that differed by fractions 6:56 of a percent. One fluid showed a slightly lower mortality rate than 7:00 another, or an intervention nudged an outcome just enough to cross a p value 7:05 threshold. And again, this matters. Precision matters, but it also made me 7:10 ask, are we mistaking statistical cleanliness for clinical impact? And 7:15 beyond that, are we even asking the right question? 7:18 Many of these studies are designed to isolate a single variable and measure a 7:22 single outcome. But patients don't live in single variables. They live in 7:27 systems. A modest change in one lab value or one endpoint may not translate 7:32 into a meaningful shift in the overall trajectory of health. This becomes 7:36 especially important when we talk about relative risk versus absolute risk. A 7:40 distinction that I think is rarely explained to patients and frankly not 7:43 always sufficiently interrogated by clinicians either. Relative risk makes 7:47 effects look dramatic. So a therapy that reduces risk by 20 to 30% sounds 7:52 powerful. But when you look at the absolute numbers, that reduction may 7:57 only represent a change from let's say 5 to 4%. That may be statistically 8:01 impressive, but clinically it is a very different conversation, especially when 8:06 you factor in side effects, cost, and long-term burden. We see this across 8:10 medicine. Medications are often framed as outcome changing based on relative 8:15 risk reductions, while the absolute benefit to an individual patient may be 8:19 modest. Meanwhile, we have interventions that do affect multiple systems like 8:23 sleep, nutrition, stress physiology, and inflammation that are dismissed because 8:28 they don't fit neatly into reductionist study designs, even when their real 8:32 world impact may be equal or greater. This distinction becomes especially 8:36 important when we look at how efficacy itself is defined, particularly in 8:40 oncology. Many cancer drugs are approved by the FDA based on demonstrated 8:44 efficacy with acceptable toxicity. But what often gets lost is that efficacy 8:50 does not necessarily mean improved survival. 8:54 For years, a significant number of oncology drugs were approved not because 8:58 they extended life expectancy, but because they met a surrogate endpoint 9:02 known as partial tumor response rate. So this meant the drug was shown to shrink 9:06 the primary tumor by more than 50% in volume. And on paper that looks like a 9:11 success. Tumors are smaller, imaging improves, biomarkers move in the right 9:15 direction. But when researchers later examined long-term outcomes, many of 9:20 these drugs did not meaningfully improve overall survival, tumor shrinkage, while 9:25 visually compelling, turned out to be a poor proxy for whether patients actually 9:29 lived longer or better. Now, this is not a critique of oncology or drug 9:33 development. It's just an illustration of a much larger issue. We often mistake 9:38 improvement in a measurable outcome for improvement in a meaningful one. And 9:43 this happens because surrogate endpoints are easier to study. They're faster to 9:47 measure and more compatible with reductionist trial designs. But 9:50 honestly, patients don't ultimately care whether a tumor shrinks by 50%. They 9:54 care whether they live longer, suffer less, and maintain quality of life. And 9:59 this brings us back to relative risk versus absolute risk and to the broader 10:03 question of how evidence is framed. A therapy can look impressive when
Chronic Disease as a Systems Problem 10:07 outcomes are presented in relative terms or when surrogate markers improve. But 10:11 when you zoom out and examine absolute benefit, system level impact, and lived 10:15 experience, the story changes. So the questions I keep coming back to are 10:20 these. Does this intervention meaningfully change a patient's life? 10:24 Does it address the system or does it simply shift one measurable outcome? 10:30 Because evidence-based medicine was never meant to be about chasing 10:33 statistically significant numbers in isolation. It was meant to guide 10:37 decisions that improve real human lives. Another foundational issue in how we 10:42 generate evidence is who that evidence is based on. Randomized control trials 10:47 rely on strict inclusion and exclusion criteria. And there's a reason for that. 10:51 These criteria are designed to isolate variables. They allow researchers to 10:56 answer a very specific question. Does this intervention work under controlled 11:00 conditions? And again, that rigor is essential. Without it, we would not know 11:05 whether a drug or intervention has true effect at all. 11:09 But the phrase isolate variables is the key because what it also means is that 11:14 the evidence is often generated in highly selective populations. Patients 11:18 who have multiple chronic conditions are excluded. People on multiple medications 11:22 are excluded. Pregnant women are excluded. Older adults are excluded. 11:27 Anyone who introduces noise into the data is removed. So what we are left 11:31 with is a version of the human body that is cleaner, simpler, and far more 11:35 uniform than what real life looks like. So doctors do look at a study and ask 11:39 whether the results are translatable to broader populations. But in my opinion, 11:44 I don't think that this step is interrogated deeply enough. Guidelines 11:47 are written, recommendations are made, and those recommendations are applied 11:51 widely, often to patients who look nothing like the population being 11:55 studied. So this is the paradox. We must study interventions this way to 12:00 establish causality. But doing so severely limits real world 12:05 applicability. Human beings are not controlled experiments as much as we 12:09 want them to be and as much as we must study them this way right now to advance 12:14 medicine. But every patient comes with a unique combination of genetics, comorbid 12:19 conditions, medications, environmental exposures, stress physiology, sleep 12:25 patterns, nutrition, and lived experience. Yet we often act as though 12:29 evidence generated in a narrow slice of the population can be cleanly 12:32 extrapolated to everyone else. I think this limitation becomes even more 12:36 exaggerated when we talk about women's health. For decades, women were not 12:40 included in clinical trials due to concerns about hormonal variability, 12:44 pregnancy risk, and reproductive potential that led women to be left out 12:48 of drug studies and biomedical research well into the late 20th century. As a 12:53 result, much of what we consider foundational medical evidence was 12:57 generated primarily in male bodies and then generalized to women after the 13:01 fact. And even today, women's health remains significantly underfunded and 13:05 underresarched relative to disease burden. Conditions that 13:08 disproportionately affect women like autoimmune disease, chronic pain 13:12 syndromes, functional GI disorders, and of course, hormonal disorders are often 13:17 less wellstudied, less well understood, and more likely to be dismissed when 13:21 objective findings are limited. And this is not because these conditions are less 13:25 real. It's because our research framework have historically struggled to 13:28 study complex system level and hormonally dynamic states. So when 13:33 patients, especially women, are told their labs are normal, but they don't 13:37 feel well, that is not a failure or imagination on their part. It is a 13:41 failure of the evidence base to reflect the full complexity of their physiology. 13:46 And this is where cracks begin to show in a purely reductionist interpretation 13:49 of evidence-based medicine. Again, not because the evidence is wrong, but 13:53 because it's incomplete. Even when evidence is strong, the model 13:58 we use to interpret it increasingly does not match the reality of modern disease. 14:03 Reductionism is not inherently bad. It is the foundation of how we learned 14:06 anatomy, physiology, pharmarmacology. You break down the system into parts, 14:11 study one variable at a time, establish causality. That approach is why we have 14:15 antibiotics, why we have surgical breakthroughs, and why we can treat 14:19 acute disease with precision. But the more time I spend in medicine, the 14:23 clearer it becomes that many of the conditions driving suffering today are 14:27 not linear problems. They are system level problems. And this isn't just me 14:32 as a sole doctor postulating. Research is emerging consistently that validates 14:37 what many functional integrative clinicians have been circling around for 14:41 years. Chronic disease involves networks, not isolated organs. So take 14:46 mental health. We are watching the science around the gut microbiome and 14:49 psychiatric symptoms evolve in real time. Human studies continue to show 14:54 associations between gut microbial patterns and depressive symptoms. And we 14:58 have meta analysis of microbiome target interventions like probiotics and 15:02 symbiotics that suggest modest but meaningful improvements in depression 15:06 and anxiety in certain populations. Is this definitive? No. The field is 15:11 heterogeneous and messy. But the direction is clear. The gut, immune 15:15 signaling, metabolic pathways and brain function are not separate categories. 15:20 They are interacting systems. Another example we can think of is cardioabolic 15:24 disease. So the older model was almost entirely lipid centered. But the modern 15:29 evidence base increasingly supports chronic low-grade inflammation as a 15:33 major driver of atherosclerosis and cardiovascular risk independent of LDL. 15:38 And we have major scientific statements and reviews that are now explicitly 15:41 emphasizing inflammatory signaling pathways like IL1, IL6, CRP as part of 15:47 the cardiovascular story. We have outcome level trials that made this hard 15:51 to ignore. When anti-inflammatory pathways are targeted in carefully 15:55 selected populations, event rates can shift even when cholesterol itself is 15:59 not the variable being manipulated. So, modern medicine is evolving. It is 16:03 beginning to name what many systemoriented clinicians have been 16:06 saying for a long time, which is chronic disease is frequently multiffactorial, 16:10 network-based, and interdependent. But here's the tension. Our healthcare 16:16 structure and research methods have not evolved at the same pace. We are still 16:21 deeply siloed. Specialization has been one of the greatest engines of clinical 16:25 advancement. So cardiology, gastronurology, neurology, these fields 16:30 have made extraordinary progress because experts dedicated their lives to a 16:34 nearer slice of the human physiology. And even within those fields, subsp 16:38 specialcialization has driven precision like electrophysiology, interventional 16:43 cardiology, heart failure, etc. So that is good. We need it. But as we get more 16:49 specialized, we also need the parallel evolution of a different kind of 16:52 clinician. Not just primary care generalist, but what I would like to 16:57 call explorative generalist. Clinicians who are trained to think in systems, to
Guidelines, Public Perception, and Curiosity 17:02 track patterns across organs, to hold complexity without collapsing it into 17:07 premature certainty. People who can integrate emerging science across fields 17:12 and ask what connects this rather than what silo does this belong to. This is 17:17 one reason functional medicine has resonated with me and a lot of people. 17:21 And at its best, it is a framework for exploring system level physiology. So, 17:26 gut immune brain connections, inflammatory drivers, metabolic 17:30 resilience, endocrine signaling, nutrients efficiency before disease 17:36 becomes diagnosible on a narrow lab threshold. But we also have to be honest 17:40 here. Functional medicine has been tainted in some places by wellness 17:44 culture and its own version of reductionism. 17:48 Sometimes the underlying pathophysiology is extrapolated beyond current evidence. 17:53 So claims outrun data and sometimes a complex system is reduced to a single 17:58 villain or a single magic intervention. I think a perfect example of this is the 18:02 longevity conversation around NAD. So we do have legitimate mechanistic reasons 18:07 to care about NAD biology. NAD is involved in energy metabolism, DNA 18:12 repair, cellular stress response. NAD levels appear to decline with age in 18:17 multiple models. So reductionism and marketing can easily turn that into NAD 18:24 declines with age, therefore supplementing NAD is anti-aging. And 18:29 that is an interesting hypothesis, but it is far too simple for the complexity 18:33 of aging physiology. And when you look at the human clinical literature to 18:37 date, the more honest conclusion is this. We can often raise NAD related 18:42 biomarkers, but meaningful downstream clinical benefits are not consistently 18:47 demonstrated yet. I do have a whole podcast about NAD in this topic if you 18:51 want to check it out. But my bigger point is this. Reductionism can creep in 18:56 everywhere. Not just in super specialized conventional medicine when 18:59 we mistake a biioarker for the whole patient, but also in integrative and 19:04 functional medicine spaces when we mistake a mechanistic pathway for a 19:08 guarantee of outcomes. What we really need is a medicine that can explore 19:12 without concluding too early. A medicine that can hold the rigor of 19:16 evidence-based practice while also respecting that chronic disease is 19:20 systemic, multicausal, and personalized, especially in an era where research is 19:25 rapidly proving just how interconnected the body actually is. And this brings me 19:29 to medical guidelines. So in modern medicine, organizations like the AAP, 19:35 American Academy of Pediatrics, the American College of Cardiology, American 19:39 Heart Association. So these societies publish clinical guidelines that are 19:43 widely considered the gold standard of care. These guidelines shape how we 19:47 practice. They inform board exams, malpractice standards, insurance 19:52 coverage, quality metrics, and clinical decision-m across the country. And 19:57 again, to be clear, guidelines do matter. They help standardize care. They 20:01 reduce extreme variation. They protect patients from idiosyncratic or unsafe 20:05 practice. In many ways, they do raise the floor of medicine. But somewhere 20:10 along the way, the word guideline began to be treated less like a guide and more 20:15 like scripture. There's this unspoken culture in medicine that says, "If it's 20:18 in the guideline, then it's correct. If I deviate from the guideline, I'm 20:22 practicing bad medicine." And that mindset can quietly transform 20:27 clinicians from thoughtful, curious scientists into algorithm followers, 20:32 executing protocols rather than actively engaging with evidence. So let's talk 20:37 about how guidelines are actually created. They are written by panels of 20:40 physicians and subject matter experts who review the available evidence and 20:44 then come together to make recommendations. 20:47 This process is rigorous, thoughtful, and often painstaking. 20:52 But here is the key. Guidelines are evidenceinformed, 20:56 not purely evidence dictated. Within a single guideline, recommendations can be 21:02 supported by vastly different levels of evidence. Some are grounded in large 21:06 high-quality randomized trials. Others are supported by smaller studies, 21:11 observational data, mechanistic reasoning, or importantly, expert 21:15 consensus. And expert consensus is not a flaw. We 21:19 want experienced clinicians weighing in when evidence is incomplete. Medicine 21:23 cannot wait decades for perfect data before acting. But we have to take a 21:27 step back and remember that this is still just a group of people making a 21:31 decision based on their experience and expertise. Let's not forget that they 21:35 definitely are subject matter experts. But when a recommendation supported by 21:40 consensus is treated the same as one supported by robust outcome level 21:44 evidence, a breakdown occurs. At the end of the day, these guidelines are still 21:49 the product of humans making decisions for large heterogeneous populations 21:53 based on incomplete and evolving data. This doesn't make guidelines wrong, but 21:58 it does mean that they're not infallible and they are not substitutes for 22:02 clinical judgment. And guidelines were never meant to replace thinking. They 22:06 were meant to support it. And this matters enormously in complex chronic or 22:11 system level disease where rigid adherence to algorithms can obscure 22:15 nuance, suppress curiosity, and prevent clinicians from asking whether 22:19 recommendation truly fits the patient that's actually sitting in front of 22:22 them. When guidelines become the ceiling rather than the floor of care, medicine 22:27 loses something essential, not safety, but wisdom. And then of course we have 22:33 on the other end of the spectrum another breakdown in how we understand what 22:37 evidence-based actually means and that's in public perception. So this is what we 22:42 see. A scientific paper is published. It has a carefully worded conclusion in the 22:47 title. But what is not in the title are the clear limitations and very specific 22:52 conditions under which those conclusions apply. But that part gets buried and a 22:57 headline gets written in the news. Then it continues to be reduced and reduced 23:01 and often pops up as truth in more news outlets, wellness blogs, social media 23:06 accounts, and eventually gets entirely stripped of what it actually means. So 23:10 what started as a narrow scientific finding turns into a broad definitive 23:14 claim. And we see this all the time. I think nutrition is probably one of the 23:19 most obvious examples. Let's take eggs. One year eggs are bad for cholesterol. 23:25 The next year, eggs are back. Then they're neutral. Then they're 23:28 protective. And the public, understandably, wants a final answer. 23:32 Are eggs good or are they bad? Should I eat them or avoid them? But that framing 23:37 misunderstands how science works. The question isn't whether eggs are
Integrative Medicine and Low-Risk Exploration 23:40 universally good or bad. The question is for whom, in what context, at what dose, 23:47 alongside what other dietary and lifestyle factors? Medicine and really 23:52 most complex systems that show up in life, so science, philosophy, and we'll 23:56 just say everything, don't operate in binaries, but culturally, we crave 24:02 certainty. We want checklists. We want to conquer one problem and then move on 24:06 to the next and never have to revisit it again. But if we truly did operate this 24:11 way in the world, we would still think the world is flat. Science shouldn't and 24:15 doesn't work that way. Evidence evolves, understanding deepens, new variables 24:21 emerge. What we know today is not the vital word. It's a snapshot in an 24:26 ongoing process. And this is where the public conversation around evidence 24:29 often goes wrong. Not because people are uninterested in science, but because 24:34 they've been taught to expect certainty where none actually exists. And this 24:38 brings me to my favorite part of this conversation. The space where curiosity 24:43 lives. The space between what we know and what we're still exploring. In 24:47 integrative medicine, we spend a lot of time in this space. Historically, many 24:51 of the therapies we explore were labeled quote unquote alternative. But what that 24:56 really meant was that they existed outside the dominant research and 24:59 funding structures of conventional medicine, not that they were inherently 25:03 unscientific. So practicing in this field means living with a lot of 25:07 emerging evidence and that naturally raises an important question. How much 25:12 evidence is enough to recommend something? And that is a fair question, 25:16 but I would argue that there's an even more important one, one that keeps 25:20 medicine both ethical and open-minded. Could this intervention plausibly cause 25:25 harm? And if the answer is yes, there is meaningful risk, unknown toxicity, or 25:30 the potential to interfere with essential treatment, then we absolutely 25:34 need more data before recommending it. That is non-negotiable. But if an 25:38 intervention is low risk, biologically plausible, and does not meaningfully 25:43 threaten patient safety, the calculus changes. The question becomes not, is 25:49 this proven beyond a doubt, but might this help? Is this reasonable to 25:54 explore? Is my patient interested in this? And I'll say more commonly, 25:59 patients bring me these ideas. So, the interest is already there. And also, 26:03 what is the financial cost? Is it reasonable to spend money on XYZ 26:07 intervention, taking into account its potential to help even if it's uncertain 26:11 it will or not? This is where integrative medicine often diverges from 26:15 rigid interpretations of evidence-based care. not abandoning rigor but by 26:21 incorporating risk context and patient values into decision-m I think all this 26:26 is a little bit more philosophical so let me give you a common example let's 26:30 take acupuncture for chronic pain or insomnia the data here is mixed but 26:35 consistent in one important way acupuncture does appear to help some 26:39 people effect sizes are modest results may vary by condition and individual and 26:45 mechanisms are still being explored likely involving neuroimmune modulation, 26:50 indogenous opioid release, and autonomic regulation. But the risk profile is 26:55 extremely low when performed by trained practitioners. Serious adverse effects 26:59 are rare. There's no systemic toxicity, and for many patients, the alternative 27:04 is long-term pharmacologic management with wellocumented risks. So, in that 27:09 context, the question isn't whether acupuncture is a universal solution. It 27:13 isn't. The question is, is it reasonable to explore a low-risk intervention that 27:19 may improve symptoms, especially when conventional options are limited, poorly 27:23 tolerated, or unwanted by the patient. So, this is not reckless medicine. This 27:29 is ethical curiosity. It is acknowledging uncertainty without being 27:34 paralyzed by it. It is recognizing that the absence of definitive evidence is 27:39 not the same as evidence of absence, especially when harm is unlikely and 27:44 patient autonomy is respected. And this framework applies far beyond 27:48 acupuncture. It applies to mindbody practices, light-based therapies, 27:52 nutritional interventions, and lifestyle changes that affect multiple systems at 27:56 once. But the key is not to overpromise. So not to collapse complexity into a 28:02 single fix and not to let curiosity turn into certainty too quickly as well. So I 28:07 think good medicine lives here not just integrative medicine in the balance 28:11 between humility and exploration between knowing what we do know and staying open 28:16 to what we have not fully mapped out yet. So this is where we are now. But to 28:21 understand where medicine needs to go, we also have to look backward and 28:24 forward at the same time. Little trippy here. We need to revisit clinical wisdom 28:29 that predates modern medicine. Wisdom that came from physicians like 28:33 Hypocrates and from ancient healing systems like Aruveda and traditional 28:37 Chinese medicine. And at the same time, we also need to look towards the future 28:43 toward new research methods, new frameworks, and emerging ideas like 28:47 precision medicine. Before our current model of modern medicine, healing 28:51 largely came from two places. what came from the earth and what came from 28:56 ourselves. So food, herbs, plants, and the human 29:01 capacity to think, reflect, regulate attention, and alter consciousness. 29:06 Those altering consciousness practices were often organized through rituals, 29:10 ceremonies, and what we might now label as quote unquote magical thinking. But 29:14 when you strip away the language and symbolism, much of this was actually 29:18 early mindbody medicine. It was an intuitive understanding that the body, 29:22 mind, and environment were inseparable. Then over time, medicine became 29:26 increasingly siloed and eventually placebolinded randomized control trials
Reimagining the Future of Evidence 29:31 became the gold standard for evidence. And that model did give us incredible 29:35 advances. But it also introduced a problem. 29:39 Many of the most important drivers of health cannot be studied this way. How 29:43 can you placelind meditation? How do you isolate nutrition when it affects every 29:48 system simultaneously? How do you study herbs which contain 29:53 hundreds of biologically active compounds as if they were single 29:56 molecule pharmaceuticals? So, a single medication is one molecule designed to 30:01 target one pathway. A single herb may contain hundreds of 30:05 interacting compounds working synergistically across multiple systems. 30:10 Setting both of those using the same reductionist framework simply does not 30:13 work. This same challenge also applies to psychedelics in mind body medicine. 30:18 We cannot truly place blind a full psychedelic experience. I will just 30:22 state the obvious here. You know if you've blasted off into another 30:25 dimension or not. Micro doing psychedelics may be different and fit 30:29 better into our current models of study and I'm doing an entire podcast episode 30:32 on that soon which includes how the placebo response plays a role there. But 30:37 my point here is that some interventions fundamentally resist the structures 30:41 we've built to study drugs. And even beyond that, we're now realizing we 30:45 can't really study drugs this way either. As we've explored throughout 30:48 this episode, the body cannot be reduced into isolated organs. Chronic disease is 30:54 systemwide. The heart is not just the heart. The brain is not just the brain. 30:58 We see inflammation, metabolism, immunity, and the neuroindocrine system 31:04 overlapping constantly. Our study designs haven't fully caught up to this 31:08 reality. So, how can we change this? And we're going to just postulate a little 31:12 bit here. First, I'm thinking of patternbased evidence instead of 31:16 outcomebased evidence. So, what if instead of asking does this intervention 31:21 improve a predefined outcome? We instead asked what patterns shift when this 31:27 intervention is introduced. Chronic disease doesn't move in straight 31:31 lines. It moves in constellations. We have sleep changes, energy shifts, 31:36 inflammation markers fluctuate, mood, cognition, digestion, and resilience all 31:41 evolve together. So we could begin by studying interventions, especially 31:45 lifestyle, mind body, and multicompound therapies by tracking systems level 31:50 pattern shifts over time rather than forcing them into single endpoints. 31:55 So I think this would involve longitudinal dense data from smaller 31:59 cohorts within person change over time, not just population averages and pattern 32:05 recognition across systems rather than binary outcomes. Next, I'm thinking of 32:10 precision curiosity trials. So personalized and of one at scale. The 32:15 future may not be larger randomized trials. It may be thousands of deeply 32:20 characterized individual experiments. So imagine structured, ethical, and of 32:25 one trials where patients explore low-risk interventions like nutrition, 32:29 supplements, mindbody practice while tracking individual biomarkers, 32:34 symptoms, and functional outcomes over time. I think that this framework could 32:38 treat each patient as their own control, allow interventions to be explored 32:41 responsibly, generate real world data about who benefits under which 32:46 conditions, embrace variability instead of trying to eliminate it, and instead 32:51 of asking does this work for everyone, we ask for whom does this work for and 32:54 why. That, in my opinion, is precision medicine without pretending certainty 32:59 too early. But if medicine is going to evolve, we cannot abandon rigor. But I 33:04 do think we need to expand our imagination. The future of 33:07 evidence-based medicine is not less science. It's science that can hold 33:11 complexity. Science that respects systems. Science that allows exploration 33:16 without prematurely declaring victory. So not just a return to the past. This 33:21 is a synthesis. And I think it's already beginning. So when I ask the question 33:25 that's the title of this podcast, is modern medicine still evidence-based? 33:29 The answer of course is not a simple yes or no. Evidence-based medicine is not 33:33 broken, but it has been narrowed. And in that narrowing, we have lost something 33:38 essential. Evidence was never meant to replace clinical judgment. It was meant 33:43 to inform it. It was never meant to silence curiosity. It was meant to guide 33:48 exploration. And it was never meant to reduce human 33:52 health to isolated variables. It was meant to improve real human lives. So, 33:57 as disease has become more complex, more chronic, and more systemic, our approach 34:01 to evidence must evolve alongside it. That means holding rigor and humility at 34:06 the same time. It means honoring what we know, questioning what we assume, and 34:12 staying open to what we haven't fully yet mapped. So, reclaiming evidence is 34:16 not rejecting science. It's practicing science more honestly. And restoring 34:22 clinical wisdom doesn't mean going backwards. It means remembering that 34:26 medicine has always been both a science and an art. And the future of medicine 34:30 depends on our ability to hold both. So, thank you for taking this trip with 34:36 me. An exploration meant to poke holes in familiar frameworks, question what we 34:41 think we know, and open our eyes to connections that weren't obvious before. 34:45 So, I'll end with this. Stay curious. Keep dripping. 34:51 Thanks for listening to the Trip Lab. If you liked this episode, please subscribe 34:55 and share so we can get the conversation started about integrative medicine and 34:59 psychedelics to destigmatize it and fully explore what this could mean in 35:04 the world. [music]
Comments